Clinical Trials
14 trialsNCT04305470 2026-05-18
MEN-301
NX Development Corp
Phase 3 Completed
NCT07144345 2026-04-22
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Recruiting
NCT07144852 2026-04-22
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Recruiting
NCT05804370 2025-10-01
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp
Phase 3 Recruiting
NCT04815083 2025-09-03
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Phase 3 Terminated
NCT01502280 2023-11-24
BALANCE
St. Joseph's Hospital and Medical Center, Phoenix
Phase 3 Completed
NCT01966120 2023-07-28
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02144077 2022-11-03
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT03024060 2017-11-07
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
DUSA Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT02799069 2017-04-28
Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02799082 2017-04-06
Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT02101931 2016-03-31
ALA
Princess Al-Johara Al-Ibrahim Cancer Research Center
Phase 3 Completed
NCT02137785 2015-09-16
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
DUSA Pharmaceuticals, Inc.
Phase 3 Completed
NCT00241670 2012-04-26
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
medac GmbH
Phase 3 Completed